These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 2083186)
61. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Homma A; Shirato H; Furuta Y; Nishioka T; Oridate N; Tsuchiya K; Nagahashi T; Aoyama H; Inuyama Y; Fukuda S Cancer J; 2004; 10(5):326-32. PubMed ID: 15530262 [TBL] [Abstract][Full Text] [Related]
62. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950 [TBL] [Abstract][Full Text] [Related]
63. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674 [TBL] [Abstract][Full Text] [Related]
64. Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer. Smith HO; Goldberg GL; Carol L; Davidson SA; Tomaino C; Centrilla L; Runowicz CD Eur J Gynaecol Oncol; 1994; 15(6):411-7. PubMed ID: 7875155 [TBL] [Abstract][Full Text] [Related]
65. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Vermorken JB; Gundersen S; Clavel M; Smyth JF; Dodion P; Renard J; Kaye SB Ann Oncol; 1993 Apr; 4(4):303-6. PubMed ID: 8518220 [TBL] [Abstract][Full Text] [Related]
67. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700 [TBL] [Abstract][Full Text] [Related]
68. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101 [TBL] [Abstract][Full Text] [Related]
69. Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee. Swenerton KD; Pater JL Semin Oncol; 1992 Feb; 19(1 Suppl 2):114-9. PubMed ID: 1411622 [TBL] [Abstract][Full Text] [Related]
71. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762 [TBL] [Abstract][Full Text] [Related]
72. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F; Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642 [TBL] [Abstract][Full Text] [Related]
73. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. Neijt JP; Engelholm SA; Tuxen MK; Sorensen PG; Hansen M; Sessa C; de Swart CA; Hirsch FR; Lund B; van Houwelingen HC J Clin Oncol; 2000 Sep; 18(17):3084-92. PubMed ID: 10963636 [TBL] [Abstract][Full Text] [Related]
74. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]
75. Superiority of carboplatin monochemotherapy over carboplatin-based polychemotherapy in ovarian cancer. Athanassiou A; Varthalitis J; Tsavaris N; Dimitriadis M; Moutzouridis G Eur J Gynaecol Oncol; 1997; 18(5):420-5. PubMed ID: 9378168 [TBL] [Abstract][Full Text] [Related]
76. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Goren MP; Forastiere AA; Wright RK; Horowitz ME; Dodge RK; Kamen BA; Viar MJ; Pratt CB Cancer Chemother Pharmacol; 1987; 19(1):57-60. PubMed ID: 2880677 [TBL] [Abstract][Full Text] [Related]
77. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123 [TBL] [Abstract][Full Text] [Related]